dc.contributor.advisor | Davies, Catharina de Lange | |
dc.contributor.advisor | Dahle, Jostein | |
dc.contributor.author | Maaland, Astri Fjelde | |
dc.date.accessioned | 2019-09-11T09:57:20Z | |
dc.date.created | 2016-06-15 | |
dc.date.issued | 2016 | |
dc.identifier | ntnudaim:14652 | |
dc.identifier.uri | http://hdl.handle.net/11250/2615568 | |
dc.description.abstract | The standard chemotherapy treatment given to newly diagnosed
Acute Myeloid Leukemia ( AML ) patients have remained practi-
cally the same for the last forty years, and is poorly tolerated by
the older patients. Several new therapies are under development,
among other targeting therapies using antibodies, and thera-
pies directed towards immune checkpoints. Antibodies target-
ing CD33 seem promising, and recently a therapeutic antibody
targeting CD37 has entered clinical trial phase I. In this mas-
ter thesis, the binding of another anti CD37 antibody, NNV003,
was measured in seven AML cell lines to find out if NNV003
could be a potential new therapy for AML . To investigate if in-
hibiting immune checkpoints could be used in AML treatments,
the expression of the immune checkpoint molecule Programmed
Death-Ligand 1 ( PD-L1 ) was evaluated in these cell lines. Flow cy-
tometry and fluorescently labeled antibodies were used to mea-
sure the CD37 and the PD-L1 expression. In addition, the pos-
sibility of a combination treatment including both the NNV003
antibody and an anti PD-L1 antibody was assessed, by investi-
gating if the PD-L1 expression was upregulated after incubation
with NNV003. NNV003 bound to all the AML cell lines, although
at a lower level than in lymphoma cell lines. The apoptosis in-
duced by NNV003 incubation was low or non existing in AML
cell lines. Only two AML cell lines seemed to have a PD-L1 expres-
sion, though very low. There was no strong correlation between
the NNV003 binding to CD37 and the expression of PD-L1 , but
a possible combination therapy can not be ruled out as the in
vitro experiments done in this study do not reflect the actual cir-
cumstances of cancer cells in a tumour microenvironment. This
first in vitro study of NNV003 binding to CD37 in AML cell
lines show promising results for using an Antibody Radionu-
clide Conjugate ( ARC ) or Antibody Drug Conjugate ( ADC ) based
on NNV003 as a new targeting therapy against AML . | en |
dc.language | eng | |
dc.publisher | NTNU | |
dc.subject | Nanoteknologi, Bionanoteknologi | en |
dc.title | Expression of two Cell Membrane Proteins, CD37 and PD-L1, in Acute Myeloid Leukemia Cell Lines | en |
dc.type | Master thesis | en |
dc.source.pagenumber | 94 | |
dc.contributor.department | Norges teknisk-naturvitenskapelige universitet, Fakultet for naturvitenskap,Institutt for fysikk | nb_NO |
dc.date.embargoenddate | 10000-01-01 | |